Eli Lilly’s diabetes and weight-loss drug Mounjaro debuts in India
Investing.com -- U.S. pharmaceutical company Eli Lilly (NYSE: LLY) has introduced its diabetes and weight-loss drug Mounjaro in India, ahead of its competitor Novo Nordisk (NYSE: NVO ). This comes as India, the world’s most populous country, faces rising levels of obesity and diabetes.
A European Medicines Agency committee, on Thursday, accepted the use of an artificial intelligence (AI) tool called AIM-NASH ...
Seeking more efficient drug development, pharmaceutical giants and startups are encouraging AI fluency and in some cases ...
24/7 Wall St. on MSN10d
2 Stocks That Could Split Very SoonStock splits tend to create a lot of buzz in the market, especially when some of the most prominent companies announce a ...
Mounjaro (tirzepatide) is a prescription drug that may be prescribed off-label for weight loss. The drug isn’t approved for this use, but it may be helpful for weight management. Mounjaro comes ...
When James Norris, a 56-year-old mechanic from Roxbury, New Jersey, went on a low dose of Mounjaro, a GLP-1 medication similar to Ozempic, to lose weight in March 2023, he thought it would be a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback